title: Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy.
abstract: BACKGROUND
  Thrombolytic therapy reduces mortality after acute myocardial infarction, even when treatment is initiated relatively late after onset of symptoms. The mechanism underlying this survival benefit is incompletely understood.
  
  
  RESULTS
  In a prospectively designed ancillary study of a randomized, placebo-controlled trial of late thrombolytic therapy (LATE), the signal-averaged (SA) ECG was recorded before hospital discharge in an effort to assess the effect of thrombolytic therapy on arrhythmia substrate. Three hundred ten patients were enrolled at 23 participating sites; 160 patients received placebo, and 150 patients received recombinant tissue-type plasminogen activator (rTPA) therapy 6 to 24 hours after onset of symptoms. Compared with placebo, rTPA tended to reduce the frequency of SAECG abnormality (filtered QRS duration > 120 milliseconds) by 37% (95% CI, -64%, +6%; P = .087) and the filtered QRS duration (105.7 +/- 13.8 versus 108.8 +/- 14.6 milliseconds, P = .05). In the prespecified subgroup of 185 patients with ST elevation on the qualifying ECG, rTPA resulted in a 52% reduction (95% CI, 4% to 77%, P = .011) of SAECG abnormality and a shorter filtered QRS duration (105.7 +/- 10.9 versus 110.7 +/- 15.9 milliseconds, P = .01). No benefit was seen in patients without ST elevation on ECG.
  
  
  CONCLUSIONS
  Late thrombolytic therapy produced a more stable electrical substrate, which probably represents an important mechanism of mortality benefit.
authors.affiliation: Division of Cardiology, St Luke's-Roosevelt Hospital Center, New York, NY 10025.
authors.forename: J S
authors.initials: JS
authors.lastname: Steinberg
authors.forename: J S
authors.initials: JS
authors.lastname: Hochman
authors.forename: C D
authors.initials: CD
authors.lastname: Morgan
authors.forename: P
authors.initials: P
authors.lastname: Dorian
authors.forename: C D
authors.initials: CD
authors.lastname: Naylor
authors.forename: P
authors.initials: P
authors.lastname: Theroux
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: P W
authors.initials: PW
authors.lastname: Armstrong
mesh_terms: D004311:Double-Blind Method; D004562:Electrocardiography / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors; D012815:Signal Processing, Computer-Assisted; D017180:Tachycardia, Ventricular / Q000453:epidemiology; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator